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Background: A. baumannii has emerged as an important nosocomial pathogen with an outstanding ability to
acquire multidrug resistant mechanisms. In this study, we investigate the molecular epidemiology and carbapenem
resistance mechanisms of A. baumannii in Tripoli, Northern Lebanon.
Methods: One hundred sixteen non-duplicate isolates isolated between 2011 and 2013 in different hospitals in
Tripoli, Lebanon from Lebanese patients and wounded Syrian patients during Syrian war were studied. Antibiotic
susceptibility testing was determined by agar disc diffusion and Etest. Carbapenemase-encoding genes were
investigated by PCR. All isolates were typed by blaOXA-51-like sequence based typing (SBT) and 57 isolates were also
analysed by MLST using Pasteur’s scheme followed by eBURST analysis.
Results: Of the 116 isolates, 70 (60 %) showed a carbapenem resistance phenotype. The blaOXA-23 with an upstream
insertion of ISAba1 was the major carbapenem resistance mechanism and detected in 65 isolates. Five isolates, including
four from wounded Syrian patients and one from a Lebanese patient, were positive for blaNDM-1. blaOXA-51-like SBT revealed
the presence of 14 variants, where blaOXA-66 was the most common and present in 73 isolates, followed by blaOXA-69 in 20
isolates. MLST analysis identified 17 sequence types (ST) and showed a concordance with blaOXA-51-like SBT. Each clonal
complex (CC) had a specific blaOXA-51-like sequence such as CC2, which harboured blaOXA-66 variant, and CC1 harbouring
blaOXA-69 variant. NDM-1 producing isolates belonged to ST85 (4 Syrian isolates) and ST25 (1 Lebanese isolate).
Conclusions: Our results showed a successful predominance of international clone 2 with a widespread occurrence of
OXA-23 carbapenemase in Lebanese hospitals. These findings emphasise the urgent need of effective measures to control
the spread of A. baumannii in this country.
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A. baumannii is an opportunistic pathogen mainly in-
volved in healthcare-associated infections, with increased
mortality and morbidity [1]. The serious concern associ-
ated with this bacterium is the increasing prevalence of
multidrug resistant isolates, especially carbapenem re-
sistant ones [2]. Therefore, management of infections
due to A. baumannii has become a real public health
issue in many countries [3]. In a recent SENTRY Anti-
microbial Surveillance program, the percentage of A.
baumannii isolates susceptible to meropenem decreased
noticeably from 52.9 % in 2009 to 37.7 % in 2011 in
European intensive care units [4]. The main mechanism
of resistance to carbapenems is the production of oxacil-
linases encoded mostly by blaOXA-23-like, blaOXA-24-
like, blaOXA-58-like and recently blaOXA-143-like and
blaOXA-235-like [2, 5–7]. To a lesser degree, carbape-
nemases from classes A and B have also been involved
[2, 5]. New Delhi metallo-ß-lactamase 1 (NDM-1), a re-
cent described metallo-ß-lactamase, has emerged in
Enterobacteriaceae as well as in Acinetobacter [8]. Gen-
erally, a limited number of clones are responsible for
worldwide outbreaks, and international clones I and II
are the most common ones [9]. In order to identify and
track these clones during hospital outbreaks, numerous
molecular typing methods have been proposed such as
pulsed-field gel electrophoresis (PFGE), amplified frag-
ment length polymorphism (AFLP), repetitive-sequence-
based PCR (rep-PCR), and multilocus sequence typing
(MLST) [10–14] . Currently, MLST is the gold standard
typing tool for population structure and macro-
epidemiological investigations based on sequencing of
internal fragments of 7 genes [14]. Two MLST schemes
have been developed for Acinetobacter baumannii : Pas-
teur and Bartual schemes [10, 15]. Overall, the 2
schemes are concordant [14]. However, because of re-
combination bias observed on some loci in Bartual’s
MLST (gyrB and gpi) [16, 17], Pasteur’s MLST has been
chosen for this study. Recently, blaOXA-51-like
sequence-based typing (SBT), a simple typing method
based on sequencing of the full length of blaOXA-51-
like gene has been proposed as it has shown a similar dis-
criminatory power than rep-PCR, and MLST [16, 18–20].
In Lebanon, limited numbers of epidemiological stud-
ies concerning A. baumannii have been reported, almost
in Beyrouth [20–23]. In a previous study, we have de-
scribed the dominance of international clone II within a
set of 42 isolates collected from Beyrouth and North
Lebanon between 2009–2012 [20]. In another study, we
reported the first detection of four NDM-1 producing
isolates isolated in Tripoli-Northern Lebanon from Syr-
ian patients injured during Syrian War [24]. The aim of
this study was to characterise A. baumannii molecular
epidemiology in Tripoli-Lebanon between 2011–2013using blaOXA-51-like and Pasteur’s MLST typing and
to determine the carbapenem resistance mechanisms.
Results
Bacterial isolates and identification
A total of 116 non-duplicate isolates were obtained be-
tween 2011 and 2013 from seven medical institutions in
Tripoli: 73 isolates from Tripoli Governmental hospital,
34 from Nini hospital, four from Dar Al Chiffaa hospital,
two from Monla, one isolate from each Hanane and
Haykal hospitals and one from the private laboratory.
Among those isolates, 59 had been obtained from Syrian
refugees and 57 from Lebanese patients. They were all
confirmed as A. baumannii by blaOXA-51 real time PCR
and rpoB gene sequencing. These isolates were recov-
ered from respiratory specimens (25/116; 21.6 %);
wound (68/116; 58.6 %); urine (10/116; 8.6 %); catheter
tips (8/116; 6.9 %), blood (1/116; 0.9 %) and other loca-
tions (3/116; 2.6 %). For one isolate, no information was
available. Ninety patients were male and 26 female. Ages
were between 1 month and 89 years with a mean of
40 years.
Antibiotic susceptibility and carbapenem resistance
mechanisms
Most of the isolates exhibited multidrug-resistant phe-
notypes. Overall, 70 isolates were carbapenem resistant
and among them, 65 carried the blaOXA-23 gene while 5
isolates carried the blaNDM-1 gene. ISAba1 was found in
101 isolates. The presence of ISAba1/blaOXA-23 associ-
ation was confirmed in all OXA-23 producing isolates.
The ISAba1/blaOXA-51 association was not detected.
Among carbapenem-resistant A. baumannii, 43 had
been isolated from Syrian refugees and 27 from
Lebanese patients. The prevalence of carbapenem resist-
ance was significantly higher among A. baumannii iso-
lated from Syrian refugees (74 % vs. 47 %; P < 0.01).
Epidemiological typing
The blaOXA-51-like SBT revealed the presence of 14 differ-
ent nucleotide variants. Of the 116 isolates, blaOXA-66
variant was the most prevalent and found in 73 isolates,
followed by blaOXA-69 (20 isolates), blaOXA-64 (7 isolates),
blaOXA-94 (5 isolates) and blaOXA-120 (2 isolates). Other
variants, blaOXA-70, blaOXA-71, blaOXA-104, blaOXA-121,
blaOXA-132, blaOXA-406, KF048914, KJ584924, and
AKAS01000012 were present sporadically in our collec-
tion. blaOXA-406 variant encoded a new protein (OXA-406)
described for the first time in this study which differed
from OXA-106 protein by a single amino acid at position
146 (lysine instead of asparagine).
MLST was performed on a set of 57 randomly selected
A. baumannii isolates representing all blaOXA-51 vari-
ants. A total of 17 ST(s), including 4 new ST(s), were
Rafei et al. BMC Microbiology  (2015) 15:103 Page 3 of 7identified (Table 1, Fig. 1). eBURST analysis showed that
12 of the 17 ST(s) were clustered into 9 CCs which were
CC1, CC2, CC3, CC25, CC33, CC85, CC149, CC158,
CC462. Additionally, ST108, ST150, ST154 were single
locus variants of ST112, ST444 and ST611 respectively,
and ST103 and ST461 were singletons.
Comparison between MLST and blaOXA-51-like SBT
showed that isolates belonging to the same clonal com-
plex carried all the same blaOXA-51 variant. Besides, each
of the remaining lineages (single locus variants or single-
tons) that were identified had additionally a specific
blaOXA-51-like variant (Table 1).
Discussion
Our study provided a global view of molecular epidemi-
ology of A. baumannii isolates from hospitals in Tripoli,
Lebanon. Tripoli is a city that hosts a large number of
refugees and wounded Syrians, which may explain the
high number of wound specimens in our collection. Al-
though, A. baumannii is an opportunistic nosocomial
pathogen, it is increasingly reported from infections oc-
curring outside hospitals, particularly skin and soft-
tissue infections and pneumonia [25]. A. baumannii has
also been a well-documented pathogen associated with
wound infections in USA troops from the Iraq and







CC IMP R Hospitals (No. of
73 blaOXA-66 ST2 (21) CC2 56R TGH (50), Nini (1
(2), private labor
Haykal (1), Dar A
Hanane (1).
20 blaOXA-69 ST1 (12) CC1 9R TGH (17), Nini (3
ST460 (2)
5 blaOXA-94 ST85 (4) CC85 4R TGH (5)
ST6 (1)
7 blaOXA-64 ST25 (6) CC25 1R Nini (7)
1 blaOXA-70 ST103 (1) Singleton S Nini
1 KF048914 ST154 (1) C S Nini
1 blaOXA-71 ST3 (1) CC3 S Nini
1 KJ584924 ST158 (1) CC158 S Nini
1 blaOXA-104 ST46 (1) CC149 S Nini
2 blaOXA-120 ST459 (1) CC33 S Nini
ST284 (1)
1 blaOXA-121 ST150 (1) C S Nini
1 blaOXA-132 ST108 (1) C S Nini
1 blaOXA-406 ST461 (1) Singleton S TGH
1 AKAS01000012 ST462 (1) CC462 S Nini
CC : clonal complex; C : complex formed by two sequence types (no number was a
imipenem, ST : sequence type, R : resistance and S : susceptible. Bold type indicatessituations raised questions about their origins and the
potential involvement of an environmental reservoir
[25]. The origin of infections from Syrian patients was
ambiguous. Although it was likely that nosocomial infec-
tions occurred, a number of infections were present at
the time of admission of the patients in Lebanese hospi-
tals [24]. These infections may have been acquired from
environmental sources at the time of injury, during the
patient stay in Syrian hospitals, or during a direct evacu-
ation from the theatre of operations to Lebanon. Unfor-
tunately, data concerning the date of injury, the length
of hospitalisation, and the conditions of care and treat-
ment in Syrian hospitals are lacking.
Approximately 60 % of our isolates showed a carba-
penem resistance phenotype. The production of OXA-
23 was the major carbapenem resistance mechanism,
with an upstream insertion of ISAba1, thus supporting
international data about the worldwide emergence of
this carbapenemase [28–30]. Alarmingly, 5 NDM-1 pro-
ducing isolates have been detected from 4 Syrian pa-
tients [24] and one from a Lebanese patient.
blaOXA-51-like is an intrinsic oxacillinase gene naturally
occurring in A. baumannii, and more than 95 variants
have been identified to date [31]. However, the occa-
sional detection of blaOXA-51 in Acinetobacter nosoco-
mialis and Acinetobacter genomic species “close toed
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Fig. 1 Population snapshot analysed by eBURST on 634 sequences present in MLST Pasteur database (last update 22.10.2014). Red circle showed
identified sequence types in this study
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Therefore, it is always combined with others techniques
[32, 33]. Genetic diversity of blaOXA-5 gene has been ex-
plored and found to be very interesting for identifying
epidemic clones [16, 18, 19, 34, 35]. Thus, the full gene
sequencing has been proposed as a single typing method
for A. baumannii. As being simple and rapid, we have
initially screened here the epidemiological belonging of
our isolates to the previous identified clonal lineages by
blaOXA-51-like SBT. We have then randomly selected iso-
lates from each of the representative blaOXA-51-like se-
quences for MLST analysis. In our study, blaOXA-51-like
gene sequencing correctly assigned all isolates to their
corresponding clonal complexes. Here, the blaOXA-66
gene variant, which is associated with ST2 (belonging to
CC2) [16, 19, 35, 36], was predominant and found in 63
% of the A. baumannii isolates. The isolates carrying the
blaOXA-66 gene variant have been identified in samples
obtained from the different hospitals in Tripoli. These
findings are consistent with those observed worldwide
since CC2 was reported in more than 34 countries in
Europe, Asia, Africa, Australia, USA, and South America
[36]. Eighty percent of our carbapenem resistant isolates
belonged to this clone and OXA-23 was the only carba-
penem resistance mechanism found. The high level of
antimicrobial resistance may represent one of the maincauses for its propensity and its successful predominance
in hospitals throughout the world [10, 36]. The blaOXA-
69 gene variant was the second gene mostly found in
our collection. This gene was commonly associated
with ST1 (belonging to CC1) but interestingly, we
found two blaOXA-69 isolates belonging to the new se-
quence type ST460 (SLV of ST1). Both isolates were
isolated from wounded Syrian patients. The blaOXA-94
was another blaOXA-51-like gene variant found in our
study, it was associated with clonal complex CC85
(named as CC6 in the study of Pournaras et al. [19]).
CC85 is currently formed by ST6, ST85, ST464, and
ST528. In our study blaOXA-51-like SBT revealed the
same sequence blaOXA-94 variant in the two identified
sequences ST6 and ST85. We have recently detected
ST464 in chicken and we found blaOXA- 94 as a blaOXA-
51 variant [37]. Our 4 NDM-1 producing Syrian isolates
belonged to ST85. Indeed, this ST has also been re-
sponsible for an outbreak in France. It is usually
imported from North Africa [38, 39] and seems to be
an emerging clone.
blaOXA-64 is a blaOXA-51-like variant associated with
CC25 [19]. ST25 (the founder of CC25) was also an
emerging clone reported in Europe, Asia, Africa and
USA [36, 40], and from pets in Reunion Island, a French
territory located in Western Indian Ocean [41].
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clone, as OXA-23, OXA-24 and OXA-58 [36]. Otherwise,
NDM-1 producing ST25 was also detected in Germany
and Kenya [41–43]. Within our four identified isolates be-
longing to ST25, one isolate was a NDM-1 producing iso-
late recovered from a urine sample of an 80-year-old
Lebanese patient suffering from amyloidosis and anaemia
at Nini hospital, Tripoli, Lebanon. Finally, compared to
carbapenem resistant isolates belonging to successful
emerging clones, most of susceptible isolates were very di-
verse, belonging to different sequence types (Table 1).
Conclusions
In conclusion, this study highlights the emergence of
NDM-1 and OXA-23 carbapenemases in Tripoli, Lebanon
and the urgent need of effective measures to control the
spread of A. baumannii in this country. It is noteworthy
that Tripoli is located near the Syrian border and the mi-
crobial epidemiology is probably highly impacted by
wounded Syrian refugees who can represent a reservoir of
multidrug-resistant bacteria in hospitals. The higher preva-
lence of carbapenem-resistant A. baumannii among isolates
from Syrian refugees was consistent with this hypothesis.
Besides, we showed that blaOXA-51-like SBT is a reliable and
fast method able to assign our isolates to their clonal com-
plexes. Other multicentre studies are required to investigate
the situation in other Lebanese cities that are possibly less
concerned by the afflux of Syrian refugees fleeing war.
Methods
Bacterial isolates and Identification
The A. baumannii clinical isolates used in this study
were collected between 2011 and 2013 from microbio-
logical laboratories covering 6 hospitals in Tripoli,
Lebanon: Tripoli Governmental hospital (100 beds), Nini
(120 beds), Dar Al Chiffaa (120 beds), Monla (120 beds),
Hanane (45 beds), and Haykal (125 beds) hospitals and
one private laboratory. Isolates were sent to Azm Center
for Research in Biotechnology and its application and
stored at-80 °C. This study was also approved by the eth-
ical committee of Azm center under the authorization N
° 07/2012. Bacterial identification was initially performed
by matrix assisted laser ionization time of flight mass
spectrometry (MALDI-TOF MS) using the Vitek®MS
(bioMérieux, Marcyl’Étoile, France) and the identifica-
tion of A. baumannii at species level was confirmed by
real time PCR of the blaOXA-51 gene [44] and partial
RNA polymerase ß-subunit (rpoB) gene sequencing [45].
Susceptibility testing and detection of carbapenemases
Antibiotic susceptibility testing was performed by the
disc diffusion method according to the recommenda-
tions of the French Society of Microbiology (www.sfm-
microbiologie.org/). A panel of 14 antibiotics was testedincluding ticarcillin, ticarcillin/clavulanic acid, piperacillin/
tazobactam, ceftazidime, imipenem, ciprofloxacin, amika-
cin, gentamicin, tobramycin, trimethoprim/sulfamethoxa-
zole, colistin, netilmicin, doxycycline and rifampicin.
Carbapenem resistance was confirmed by determining
minimum inhibitory concentration (MICs) against imipe-
nem, meropenem and doripenem by Etest®strips (bioMér-
ieux). Carbapenem resistant isolates were investigated by
PCR assays for the presence of carbapenemase-encoding
genes blaOXA-23 [46], blaOXA-24 [46], blaOXA-58 [46],
blaOXA-143 [6], blaNDM-1 [47], blaIMP [5], blaVIM [5], blaKPC
[48] and the insertion sequence ISAba1 [49]. The presence
of ISAba1 upstream blaOXA-23 or blaOXA-51 genes was
searched using a combination of ISAba1 primers with re-
verse primers of blaOXA-23 or blaOXA-51 respectively.
Epidemiological typing
Epidemiological typing of all isolates was carried out by
blaOXA-51-like sequence based typing (SBT) as described
previously [16]. The sequences were compared to all var-
iants present in BLAST. Each new sequence detected
was submitted to GenBank and assigned by Lahey data-
base for beta-lactamase classification (http://www.la-
hey.org/studies/webt.asp). MLST was performed on a
panel of 57 isolates according to the Pasteur scheme
(http://www.pasteur.fr/mlst). When a new allele or a
new sequence type (ST) was identified, it was submitted
to Pasteur Institute MLST Database. eBURST (http://
eburst.mlst.net/) was applied to compare identified ST(s)
to available ST(s) present in MLST Database (last update
22.10.2014). A clonal complex (CC) was defined as a set
formed by the founder ST and its single locus variants
(SLV) [10].
Nucleotide sequence accession numbers and novel
sequence types
Four newly identified ST(s) have been coded by MLST
Pasteur as ST459, ST460, ST461 and ST462. A new nu-
cleotide variant of blaOXA-51 was submitted to GenBank
under the submission number [GenBank: KJ584915] and
assigned by Lahey center as blaOXA-406.
Statistical analysis
The comparison of the prevalence of carbapenem-resistant
A. baumannii in isolates from Syrian refugees and in
isolates from Lebanese patients was performed with the
Chi-square for test. A P < 0.05 was considered significant.
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